Global R&D Pipeline
My Favorite
Hot Targets:
CD3
Back
Total number of drugs
846
Phase II and later clinical stages
5%
Involving companies
755
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M-701 | M-701 | Bispecific T-cell Engager (BiTE) | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases Other Diseases Respiratory Diseases | CD3 stimulants EpCAM modulators | Wuhan YZY Biopharma Co., Ltd. | Wuhan YZY Biopharma Co., Ltd. | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | M-701 | - | - | detail > | |
| Mouse monoclonal antibody against human CD3 antigen of T lymphocyte(Wuhan Institute of Biological Products Co., Ltd.) | Mouse monoclonal antibody against human CD3 antigen of T lymphocyte(Wuhan Institute of Biological Products Co., Ltd.) | Monoclonal antibody | Immune System Diseases | CD3 inhibitors | Wuhan Institute of Biological Products Co., Ltd. | Wuhan Institute of Biological Products Co., Ltd. | Approved | Approved | China | 1999-01-01 | 1999-01-01 | - | - | - | - | - | Mouse monoclonal antibody against human CD3 antigen of T lymphocyte(Wuhan Institute of Biological Products Co., Ltd.) | - | - | detail > | |
| Brenetafusp | Brenetafusp | TCR fusion protein | Neoplasms Skin and Musculoskeletal Diseases Endocrinology and Metabolic Disease Respiratory Diseases Urogenital Diseases Hemic and Lymphatic Diseases | CD3 stimulants PRAME inhibitors Immunologic cytotoxicity | Immunocore Ltd. | Immunocore Ltd. Immunocore Holdings Plc | Phase 3 | - | - | - | - | - | - | - | - | - | Brenetafusp | - | - | detail > | |
| Xaluritamig | Xaluritamig | Bispecific T-cell Engager (BiTE) | Neoplasms Urogenital Diseases | CD3 stimulants STEAP1 modulators | Amgen, Inc. | Amgen, Inc. BeiGene (Beijing) Co. Ltd. Xencor, Inc. | Phase 3 | Phase 1 | - | - | - | - | - | - | - | - | Xaluritamig | - | - | detail > | |
| Alveltamig | Alveltamig | Trispecific T-cell engager (TriTE) | Neoplasms Urogenital Diseases Respiratory Diseases | CD3 stimulants DLL3 inhibitors | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | Phase 3 | Phase 3 | - | - | - | Breakthrough Therapy（China） Orphan Drug（United States） | - | - | - | - | Alveltamig | - | - | detail > | |
| CM-336 | CM-336 | Bispecific T-cell Engager (BiTE) | Neoplasms Immune System Diseases Endocrinology and Metabolic Disease Hemic and Lymphatic Diseases Other Diseases Skin and Musculoskeletal Diseases | BCMA inhibitors CD3 stimulants | Keymed Biomedical Technology (Chengdu) Co., Ltd. | Keymed Biomedical Technology (Chengdu) Co., Ltd. Ouro Medicines, Inc. Keymed Biosciences, Inc. | Phase 3 | Phase 3 | - | - | - | Orphan Drug（United States） | - | - | - | - | CM-336 | - | - | detail > | |
| QLS-31905 | QLS-31905 | Bispecific T-cell Engager (BiTE) | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Other Diseases | CD3 stimulants CLDN18.2 inhibitors | Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | QLS-31905 | - | - | detail > | |
| Linvoseltamab-gcpt | Linvoseltamab-gcpt | Bispecific T-cell Engager (BiTE) | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Endocrinology and Metabolic Disease Other Diseases | BCMA inhibitors CD3 stimulants | Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. Regeneron Ireland DAC | Approved | - | United States European Union Iceland Liechtenstein Norway | 2025-04-23 | - | Accelerated Approval（United States） Conditional marketing approval（European Union） Fast Track（United States） Orphan Drug（United States） Priority Review（United States） | - | - | - | - | Linvoseltamab-gcpt | - | - | detail > | |
| Pasritamig | Pasritamig | Bispecific T-cell Engager (BiTE) | Neoplasms Urogenital Diseases | CD3 stimulants KLK2 inhibitors | Janssen Research & Development LLC Zymeworks BC, Inc. | Janssen Pharmaceutica NV Thermo Fisher Scientific, Inc. Janssen Research & Development LLC | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | Pasritamig | - | - | detail > | |
| Odronextamab | Odronextamab | Bispecific T-cell Engager (BiTE) | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | CD20 inhibitors CD3 stimulants ADCC CD20-directed cytolytic effects | Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. Zai Lab (Shanghai) Co., Ltd. Regeneron Ireland DAC | Approved | Phase 3 | European Union Iceland Liechtenstein Norway | 2024-08-22 | - | Fast Track（United States） Orphan Drug（European Union） Orphan Drug（United States） Priority Review（United States） | - | - | - | - | Odronextamab | - | - | detail > |
Total 846 data
1
2
3
4
5
6
...
84
85
